Lönnkvist Karin, Anderson Martin, Hedlin Gunilla, Svartengren Magnus
Astrid Lindgren Children's Hospital, Karolinska Hospital, Stockholm, Sweden.
Pediatr Allergy Immunol. 2004 Aug;15(4):351-8. doi: 10.1111/j.1399-3038.2004.00165.x.
There is a need for controlled trials among children with asthma to evaluate and compare different markers of inflammation.
Our goal was to investigate the effect of withdrawal of inhaled budesonide on repeated measurements of exhaled NO (ENO), peripheral blood eosinophils (PBE), sputum/NAL/serum-eosinophil cationic protein (ECP), bronchial hyperresponsiveness (BHR) and forced expiratory volume in 1 s (FEV(1)) in children with allergic asthma.
Eighteen asthmatic children were randomly allocated to continue or discontinue use of inhaled budesonide. They were followed up, at six visits for 4 months with regular blood, serum, sputum, and NAL samples. Sixteen age-matched healthy children served as controls.
ENO, PBE, and S-ECP increased significantly in the withdrawal group (p < 0.05) but not in the continuous treatment group. No trend could be observed during the study for markers in sputum or in NAL in either group.
The present data provide evidence for the clinical usefulness of measuring ENO, PBE, and S-ECP and when combined they could help to avoid over- and undertreatment with corticosteroids in the growing child.
需要在哮喘儿童中进行对照试验,以评估和比较不同的炎症标志物。
我们的目标是研究停用吸入布地奈德对过敏性哮喘儿童重复测量呼出一氧化氮(eNO)、外周血嗜酸性粒细胞(PBE)、痰液/鼻咽抽吸物/血清嗜酸性粒细胞阳离子蛋白(ECP)、支气管高反应性(BHR)和一秒用力呼气容积(FEV₁)的影响。
18名哮喘儿童被随机分配继续或停用吸入布地奈德。对他们进行随访,在6次就诊时,为期4个月,定期采集血液、血清、痰液和鼻咽抽吸物样本。16名年龄匹配的健康儿童作为对照。
停药组的eNO、PBE和S-ECP显著升高(p < 0.05),但持续治疗组未升高。在研究期间,两组痰液或鼻咽抽吸物中的标志物均未观察到趋势。
目前的数据为测量eNO、PBE和S-ECP的临床实用性提供了证据,并且当它们结合使用时,可以帮助避免在成长中的儿童中糖皮质激素的过度治疗和治疗不足。